The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030. Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin, and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others). Some of the common fungal infections such as athlete’s foot, fungal meningitis, ringworm, and other infections can be treated by antifungal drugs that work by killing the fungal cells, breaking the contents of the cells. These cells eventually leak out and result in the death of the cell, which also prevent the cell to grow further, thus preventing the infection.
Growth of the anti-fungal drugs market is majorly driven by alarming rise in prevalence of chronic diseases such as diabetes and tuberculosis drives the growth of the market. In addition, growth in incidence of the prevalence rate of infectious diseases and growth in population of immuno-compromised (prone to infectious diseases) individuals contribute toward the growth of the market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period. Moreover, as per Centers for Disease Control and Prevention (CDC) estimates, there are roughly 46,000 cases of hospital-associated invasive candidiasis each year, a number that is increasing over the past two decades. Hospital-associated invasive candidiasis is among the most common bloodstream infections found in hospitalized patients, and is caused by Candida yeasts that generally dwell in the gut and on the skin with some problems. This disease has led to death in about 30% of patients with bloodstream infections. Most cases of candidiasis fungal infection occur in the U.S. and Canada. In states where blastomycosis is reportable, yearly incidence rates are approximately 1 to 2 cases per 100,000 people. In addition, surgein healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs are the factors that propel the market growth. Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.
The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region. By drug type, it is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. By therapeutic indication, it is classified into aspergillosis, dermatophytosis, candidiasis, and others. By infection type, the market is bifurcated into superficial and systemic antifungals.
By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2020, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global anti-fungal drugs market are Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Merck & Co. Inc, Novaris AG, Abbott Laboratories, GlaxosithKlinePlc, AstellasPharma Inc., Johnson & Johnson and Merz Pharma.
Growth of the anti-fungal drugs market is majorly driven by alarming rise in prevalence of chronic diseases such as diabetes and tuberculosis drives the growth of the market. In addition, growth in incidence of the prevalence rate of infectious diseases and growth in population of immuno-compromised (prone to infectious diseases) individuals contribute toward the growth of the market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period. Moreover, as per Centers for Disease Control and Prevention (CDC) estimates, there are roughly 46,000 cases of hospital-associated invasive candidiasis each year, a number that is increasing over the past two decades. Hospital-associated invasive candidiasis is among the most common bloodstream infections found in hospitalized patients, and is caused by Candida yeasts that generally dwell in the gut and on the skin with some problems. This disease has led to death in about 30% of patients with bloodstream infections. Most cases of candidiasis fungal infection occur in the U.S. and Canada. In states where blastomycosis is reportable, yearly incidence rates are approximately 1 to 2 cases per 100,000 people. In addition, surgein healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs are the factors that propel the market growth. Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.
The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region. By drug type, it is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. By therapeutic indication, it is classified into aspergillosis, dermatophytosis, candidiasis, and others. By infection type, the market is bifurcated into superficial and systemic antifungals.
By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2020, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global anti-fungal drugs market are Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Merck & Co. Inc, Novaris AG, Abbott Laboratories, GlaxosithKlinePlc, AstellasPharma Inc., Johnson & Johnson and Merz Pharma.
Key Benefits For Stakeholders
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global anti-fungal drugs market to identify the prevailing opportunities.
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Region & country-wise analysis is provided to understand the market trends and dynamics.
Key Market Segments
By Drug Class
- Azoles
- Fluconazole
- Voricanazole
- Posaconazole
- Clotrimazole
- Others
- Polyenes
- Amphotericin B
- Others
- Allylamines
- Terbinafine
- Naftifine
- Others
- Others
- Echinocandins
- Caspofungin
- Micafungin
- Others
By Infection Type
- Superficial Antifungal Infections
- Systemic Antifungal Infections
By Therapeutic Indications
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Others
By Dosage Forms
- Oral
- Topical
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Hologic, Inc
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Siemens Medical Solutions USA, Inc.
- bioMérieux SA
- Abbott
- BD
- Cardinal Health, Inc.
- F. Hoffmann-La Roche Ltd
- General Electric Company
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS
CHAPTER 5: ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE
CHAPTER 6: ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS
CHAPTER 7: ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS
CHAPTER 8: ANTIFUNGAL DRUGS MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Antifungal Drugs Market,' the antifungal drugs market size was valued at $16.6 billion in 2020, and is estimated to reach $25.0 billion by 2030, growing at a CAGR of 3.9% from 2021 to 2030.Antifungal drugs are medications that selectively eliminate fungal infections from the host. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is continuously growing and evolving owing to robust developmental efforts made by researchers and market players in the field.
Factors that drive the growth of the global anti-fungal drugs market are growth in prevalence of fungal infection, rise in awareness levels pertaining to myriad of fungal infections, and increase in demand for generic drugs. Moreover, the production of antifungal drugs by key players such as GlaxosmithKline Plc manufactures, performs R&D activities, and develops innovative products applicable in the six end core areas, respiratory, HIV &infectious diseases, vaccines, immuno-inflammation, oncology, and rare diseases. It offers more products to improve the treatment for patients, consumers, and healthcare providers. It has a significant global presence in more than 150 countries. It manufactures antifungal creams, Clioquinol, Miconazole, Nystatin, Oxiconazole, and Terbinafine. With these antifungal drugs, GSK sustains its market presence in the global antifungal drugs market.
For instance, in June 2021, Mankind Pharma announced the launch of drug named Posaconazole Gastro. They are the resistant tablets, which are used to treat black fungus. In addition, in June 2021, Cadila Pharmaceuticals launched a new triazoel antifungal drug Posaconazole that is effective against a wide range of invasive fungal diseases. In addition the drug has been recommended as a second-line treatment for mucormycosis. Thus, rise in production of new antifungal drugs by large number of key players has increased the growth of the market.
Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the anti-fungal drugs market. In addition, Fungal Genetic Resource of India (FUNGEN) was engaged in training graduate student mycologists in colleges and universities in isolation techniques, and operating on a crowdsourcing model with 'mini-collections” developed at participating centers to provide awareness about fungus, the diseases caused by them, and the treatments. Hence, such robust initiatives taken by nongovernmental organizations are expected to fuel the market growth.
The global antifungal drugs industry is segmented into drugs class, infection type, therapeutic indication type, and dosage forms. On the basis of drug class, the azoles segment is anticipated to maintain its dominance during the forecast period. This is due to the high usage of drugs such as azole for all the fungal indications and these also offer broad spectrum activity and improved safety levels. In addition, rise in prevalence of most commonly occurring systematic fungal infection such as candidiasis supplements the antifungal drugs market growth. However, the echinocandins are expected to grow rapidly throughout the forecast period. This is owing to the growth in incidence of hospital-acquired infections and increase in life expectancy among people.
The candidiasis indication is expected to register the highest CAGR of 3.7 throughout the forecast period. This is due to high incidences of skin infections in both children and adults. Aspergillosis segment generated the highest revenue in 2020, accounting for about 4.1% of the total share in 2020.
Region wise, the antifungal drugs industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Region wise, North America accounted for a majority share of the global antifungal market in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to surge in prevalence of infectious diseases such as aspergillosis, dermatophytosis, and candidiasis; increase in number of approvals for anti-fungal drugs; and presence of key players. Asia-Pacific is anticipated to witness highest CAGR during antifungal drugs market forecast owing to growth in healthcare expenditures.
Key findings of the Study
- Depending upon antifungal drugs market analysis, azoles segment among Drug class was the highest contributor in 2020.
- On the basis of infection type, systematic antifungal infection dominated the market in 2020, and is expected to continue this trend during the forecast period.
- On the basis of Therapeutic indication type, candidiasis dominated the market in 2020, and is expected to continue this trend during the forecast period.
- By dosage forms, oral segment dominated the market in 2020, and is expected to continue this trend during the forecast period
- By Region, North America accounted for a majority of the antifungal drugs market share in 2020, and is anticipated to remain dominant during the forecast period.
Companies Mentioned
- Hologic, Inc
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Siemens Medical Solutions USA, Inc.
- bioMérieux SA
- Abbott
- BD
- Cardinal Health, Inc.
- F. Hoffmann-La Roche Ltd
- General Electric Company
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | April 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 16572.1 million |
| Forecasted Market Value ( USD | $ 25045.2 million |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
